Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Sells $202,500.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Kush Parmar sold 27,000 shares of Entrada Therapeutics stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $7.50, for a total value of $202,500.00. Following the transaction, the director owned 1,093,313 shares in the company, valued at approximately $8,199,847.50. This trade represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Kush Parmar also recently made the following trade(s):

• On Friday, June 27th, Kush Parmar sold 75,000 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.91, for a total value of $518,250.00.
• On Monday, June 30th, Kush Parmar sold 25,000 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.81, for a total transaction of $170,250.00.

Entrada Therapeutics Stock Performance

TRDA traded down $0.21 during trading on Friday, reaching $6.55. The company had a trading volume of 219,912 shares, compared to its average volume of 135,518. The firm's 50-day simple moving average is $7.68 and its 200 day simple moving average is $10.32. The company has a market cap of $248.59 million, a price-to-earnings ratio of 8.09 and a beta of -0.11. Entrada Therapeutics, Inc. has a 12-month low of $6.48 and a 12-month high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.36. Entrada Therapeutics had a net margin of 14.39% and a return on equity of 5.84%. The business had revenue of $8.75 million for the quarter, compared to the consensus estimate of $10.98 million. On average, sell-side analysts expect that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Entrada Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, June 27th. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Entrada Therapeutics in a report on Tuesday, May 20th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $25.67.

Institutional Trading of Entrada Therapeutics

Hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC grew its holdings in shares of Entrada Therapeutics by 21.6% during the fourth quarter. Janus Henderson Group PLC now owns 2,080,367 shares of the company's stock valued at $36,011,000 after buying an additional 368,908 shares in the last quarter. Merck & Co. Inc. acquired a new stake in Entrada Therapeutics during the 1st quarter worth about $15,728,000. Vanguard Group Inc. grew its stake in Entrada Therapeutics by 19.7% during the 4th quarter. Vanguard Group Inc. now owns 1,464,237 shares of the company's stock valued at $25,317,000 after acquiring an additional 241,052 shares in the last quarter. Wellington Management Group LLP grew its stake in Entrada Therapeutics by 2.1% during the 1st quarter. Wellington Management Group LLP now owns 1,053,314 shares of the company's stock valued at $9,522,000 after acquiring an additional 21,488 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Entrada Therapeutics by 28.5% in the 4th quarter. Northern Trust Corp now owns 318,177 shares of the company's stock valued at $5,501,000 after purchasing an additional 70,497 shares during the period. Hedge funds and other institutional investors own 86.39% of the company's stock.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.